Poxel has set out a new vision focused on midphase programs in rare metabolic diseases. The new strategy hits pause on plans to start a phase 2b nonalcoholic steatohepatitis (NASH) trial and makes no mention of the next steps for phase 3 ready diabetes drug imeglimin.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,